Pneumonia is one of the devastating diseases that affect children under five and can result in high incidence and significant mortality rates. A substantial subset of these cases is caused by Staphylococcus aureus (S. aureus), a Gram-positive bacteria that can cause severe complications and even death. Additionally, antibiotic resistance complicates this problem further. In order to combat this issue, combining flavonoids and bacteriophage products may be a critical solution in decreasing morbidity and mortality rates of pneumonia. Apigenin, extracted from celery (Apium graveolens L.), which has anti-inflammatory and antioxidant effects. Combined with bacteriophage lysin, it can work synergistically against infections and inflammation without being easily resisted by bacteria. This literature review focuses on the use of apigenin and phage lysin, LysGH15, as a treatment for children’s pneumonia, sourced from Google Scholar and PubMed, using several combined keywords such as “new treatment”, “children pneumonia”, “Staphylococcus aureus”, “MRSA”, “new antibacterial”, and “therapy”. Combination therapy shows potential as a new treatment candidate for children’s pneumonia.